Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

akorn - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. this loss of effect appears with a variable time of onset in each patient and should be closely monitored. brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years) [see use in specific populations (8.4) ]. brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [see adverse reactions (6.1) and (6.2) ]. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rab

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

akorn - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sandoz inc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings ] ; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings ] ; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. read this instructions for use that comes with timolol maleate ophthalmic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol maleate ophthalmic solution: how should i use timolol maleate ophthalmic solution? the bottle is designed to assure the delivery of a precise dose of medication. before

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bausch & lomb incorporated - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate sterile ophthalmic gel forming solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic gel forming solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings, obstructive pulmonary disease ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings, cardiac failure ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timolol maleate ophthalmic gel forming solution 0.25% and 0.5% read this instructions for use that comes with timolol maleate ophthalmic gel forming solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timol

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

apotex corp - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution, usp 0.5% is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution  is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease (see warnings and precautions, 5.1, 5.3). timolol maleate ophthalmic solution  is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure (see warnings and precautions, 5.2 ); cardiogenic shock. timolol maleate ophthalmic solution  is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past. teratogenic effects: pregnancy category c: teratogenicity studies have been performed in animals. teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. there are no adequate and well-controlled studies in pregnant women. timolol maleate ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. timolol has been detected in human milk following oral and ophthalmic drug administration. because of the potential for serious adverse reactions from timolol maleate ophthalmic solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

oceanside pharmaceuticals - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution 0.5% is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution 0.5% is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see warnings and precautions (5.1, 5.3)]. timolol maleate ophthalmic solution 0.5% is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock [see warnings and precautions (5.2)] . timolol maleate ophthalmic solution 0.5% is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past. teratogenic effects teratogenicity studies have been performed in animals. teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exp

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - timolol maleate; brimonidine tartrate - eye drops - 5mg/1ml ; 2mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

fdc international ltd - timolol maleate - eye drops - 2.5mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

fdc international ltd - timolol maleate - eye drops - 5mg/1ml

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - timolol maleate 6,83 mg/ml - eq. timolol 5 mg/ml; dorzolamide hydrochloride 22,26 mg/ml - eq. dorzolamide 20 mg/ml - eye drops, solution - 20 mg/ml - 5 mg/ml - timolol maleate 6.83 mg/ml; dorzolamide hydrochloride 22.26 mg/ml - timolol, combinations